Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5821)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 26, 2021 (publication date) through Feb 8, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Patoulias DI, Boulmpou A, Teperikidis E, Katsimardou A, Siskos F, Doumas M, Papadopoulos CE, Vassilikos V. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol 2021; 13(10): 585-592 [PMID: 34754403 DOI: 10.4330/wjc.v13.i10.585] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v13/i10/585.htm |
| Number | Citing Articles |
| 1 |
Inês Henriques Vieira, Tânia Santos Carvalho, Joana Saraiva, Leonor Gomes, Isabel Paiva. Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus. Biomedicines 2024; 12(5): 1102 doi: 10.3390/biomedicines12051102
|
| 2 |
Elina Khattab, Michaelia Kyriakou, Elena Leonidou, Stefanos Sokratous, Angeliki Mouzarou, Michael M. Myrianthefs, Nikolaos P. E. Kadoglou. Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives. Pharmaceuticals 2025; 18(1): 134 doi: 10.3390/ph18010134
|
| 3 |
Mayra Alejandra Jaimes Campos, Iván Andújar, Felix Keller, Gert Mayer, Peter Rossing, Jan A. Staessen, Christian Delles, Joachim Beige, Griet Glorieux, Andrew L. Clark, William Mullen, Joost P. Schanstra, Antonia Vlahou, Kasper Rossing, Karlheinz Peter, Alberto Ortiz, Archie Campbell, Frederik Persson, Agnieszka Latosinska, Harald Mischak, Justyna Siwy, Joachim Jankowski. Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study. Pharmaceuticals 2023; 16(9): 1298 doi: 10.3390/ph16091298
|
| 4 |
André J. Scheen. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?. La Presse Médicale 2023; 52(1): 104158 doi: 10.1016/j.lpm.2022.104158
|
| 5 |
Angeliki Bourazana, Grigorios Giamouzis, John Skoularigis, Filippos Triposkiadis, Andrew Xanthopoulos. Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World Journal of Cardiology 2022; 14(4): 266-270 doi: 10.4330/wjc.v14.i4.266
|
| 6 |
Talip E. Eroglu, Ruben Coronel, Fredrik Folke, Gunnar Gislason. Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study. Resuscitation Plus 2024; 20: 100821 doi: 10.1016/j.resplu.2024.100821
|
| 7 |
André J. Scheen. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 2022; 48(6): 101390 doi: 10.1016/j.diabet.2022.101390
|
| 8 |
Yosuke Nabeshima, Atsushi Tanaka, Koichi Node. Sweet relationship between SGLT2 inhibition and heart failure. International Journal of Cardiology 2024; 410: 132223 doi: 10.1016/j.ijcard.2024.132223
|
| 9 |
Basavana Goudra, Geno J. Merli, Michael Green. Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications. Pharmaceuticals 2024; 18(1): 4 doi: 10.3390/ph18010004
|
| 10 |
Anastasia Nikolaidou, Ioannis Ventoulis, Georgios Karakoulidis, Vasileios Anastasiou, Stylianos Daios, Spyridon-Filippos Papadopoulos, Matthaios Didagelos, John Parissis, Theodoros Karamitsos, Kalliopi Kotsa, Antonios Ziakas, Vasileios Kamperidis. Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review. Medicina 2024; 60(6): 912 doi: 10.3390/medicina60060912
|
| 11 |
Erin S LeBlanc, Neon Brooks, Melinda Davies, Ranee Chatterjee. Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. The Journal of Clinical Endocrinology & Metabolism 2024; 109(12): e2167 doi: 10.1210/clinem/dgae655
|
| 12 |
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, Chris Stone, Krishna Bellam, Akshay Malhotra, M. Ruhul Abid, Frank W. Sellke, Meijing Wang. Dipeptidyl peptidase 4 inhibitor sitagliptin decreases myocardial fibrosis and modulates myocardial insulin signaling in a swine model of chronic myocardial ischemia. PLOS ONE 2024; 19(7): e0307922 doi: 10.1371/journal.pone.0307922
|
| 13 |
Shuyao Zhang, Fnu Sidra, Carlos A. Alvarez, Mustafa Kinaan, Ildiko Lingvay, Ishak A. Mansi. Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-54009-3
|
| 14 |
Young Sang Lyu, Seok Oh, Jin Hwa Kim, Sang Yong Kim, Myung Ho Jeong. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus. Cardiovascular Diabetology 2023; 22(1) doi: 10.1186/s12933-023-01914-4
|
| 15 |
Patryk Graczyk, Aleksandra Dach, Kamil Dyrka, Andrzej Pawlik. Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus. International Journal of Molecular Sciences 2024; 25(9): 5027 doi: 10.3390/ijms25095027
|
| 16 |
S. G. Kanorskii, Yu. S. Kovalenko. Features of development, the possibility of prevention and treatment of atrial fibrillation in patients with diabetes mellitus. South Russian Journal of Therapeutic Practice 2023; 4(1): 19 doi: 10.21886/2712-8156-2023-4-1-19-27
|
| 17 |
Mar Garcia Zamora, Gemma García–Lluch, Lucrecia Moreno, Juan Pardo, Consuelo Cháfer Pericas. Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study. Pharmacological Research 2024; 206: 107295 doi: 10.1016/j.phrs.2024.107295
|
| 18 |
Ofri Mosenzon, Alice YY Cheng, Alejandro A. Rabinstein, Simona Sacco. Diabetes and Stroke: What Are the Connections?. Journal of Stroke 2023; 25(1): 26 doi: 10.5853/jos.2022.02306
|
| 19 |
Yunwen Xu, Thomas A. Boyle, Beini Lyu, Shoshana H. Ballew, Elizabeth Selvin, Alexander R. Chang, Lesley A. Inker, Morgan E. Grams, Jung-Im Shin. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study. Journal of General Internal Medicine 2024; 39(7): 1112 doi: 10.1007/s11606-023-08589-3
|
| 20 |
Fu-Chih Hsiao, Kun-Chi Yen, Tze-Fan Chao, Shao-Wei Chen, Yi-Hsin Chan, Pao-Hsien Chu. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. The Journal of Clinical Endocrinology & Metabolism 2022; 107(9): 2493 doi: 10.1210/clinem/dgac402
|
| 21 |
Akash Fichadiya, Amity Quinn, Flora Au, Dennis Campbell, Darren Lau, Paul Ronksley, Reed Beall, David J T Campbell, Stephen B Wilton, Derek S Chew. Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. Europace 2024; 26(3) doi: 10.1093/europace/euae054
|
| 22 |
Praloy Chakraborty, Stanley Nattel, Kumaraswamy Nanthakumar, Kim A. Connelly, Mansoor Husain, Sunny S. Po, Andrew C.T. Ha. Sudden cardiac death due to ventricular arrhythmia in diabetes mellitus: A bench to bedside review. Heart Rhythm 2024; 21(10): 1827 doi: 10.1016/j.hrthm.2024.05.063
|
| 23 |
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Meha Sharma, Shinjan Patra, Saptarshi Bhattacharya. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis. Medicine 2024; 103(28): e38870 doi: 10.1097/MD.0000000000038870
|
| 24 |
C. Siafarikas, G. Karamanakos, K. Makrilakis, A. Tsolakidis, K. Mathioudakis, S. Liatis. Prevalence and Incidence of Medication-Treated Diabetes and Pattern
of Glucose-Lowering Treatment During the COVID-19 Pandemic: Real-World Data from
the Electronic Greek Prescription Database. Experimental and Clinical Endocrinology & Diabetes 2024; 132(09): 515 doi: 10.1055/a-2307-4631
|
| 25 |
I‐Weng Yen, Hung‐Yuan Li. Dipeptidyl peptidase‐4 inhibition targeting vascular senescence as a novel treatment for atherosclerosis. Journal of Diabetes Investigation 2024; 15(2): 143 doi: 10.1111/jdi.14100
|
| 26 |
Jessica Kearney, Luigi Gnudi. The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes. Pharmaceutics 2023; 15(5): 1343 doi: 10.3390/pharmaceutics15051343
|
| 27 |
Khawaja M. Talha, Gregg C. Fonarow, Salim S. Virani, Javed Butler. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal 2022; 18(5): 40 doi: 10.14797/mdcvj.1155
|
| 28 |
Binish A Ahmad, Isha M Sanghani, Rithika Sayabugari, Hannah Biju, Akshaya Siddegowda, Minnu Ittiachen Kinattingal, Sai Goutham Reddy Yartha, Prajyoth M Gaonkar, Syed Shireen Andrabi, Yogeshkumar K Vaghamashi, Arunika Korwar. Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs. Cureus 2023; doi: 10.7759/cureus.46373
|
| 29 |
Simona Sacco, Matteo Foschi, Raffaele Ornello, Federico De Santis, Riccardo Pofi, Michele Romoli. Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities. Diabetologia 2024; 67(7): 1192 doi: 10.1007/s00125-024-06146-z
|
| 30 |
Kevin Yau, Ayodele Odutayo, Satya Dash, David Z.I. Cherney. Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. Canadian Journal of Cardiology 2023; 39(12): 1816 doi: 10.1016/j.cjca.2023.07.007
|
| 31 |
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovascular Diabetology 2022; 21(1) doi: 10.1186/s12933-022-01549-x
|
| 32 |
Talip E Eroglu, Ruben Coronel, Patrick C Souverein. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. European Heart Journal - Cardiovascular Pharmacotherapy 2024; 10(4): 289 doi: 10.1093/ehjcvp/pvae022
|
| 33 |
Airi Matsuzaki, Kenji Momo, Ayako Watanabe, Hiromi Koshizuka, Yuka Kashiwabara, Katsumi Tanaka, Tadanori Sasaki. Risk Assessment for Heart Failure in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase 4 Inhibitor Using a Large Claims Dataset. Biological and Pharmaceutical Bulletin 2023; 46(9): 1217 doi: 10.1248/bpb.b23-00073
|
| 34 |
Pann Ei Hnynn Si, S. Parker, D. Abdelhafiz, A. Summerbell, S. Muzulu, Ahmed H. Abdelhafiz. Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review. Diabetes Research and Clinical Practice 2024; 211: 111662 doi: 10.1016/j.diabres.2024.111662
|
| 35 |
Dwight D. Harris, Sharif A. Sabe, Mark Broadwin, Krishna Bellam, Cynthia M. Xu, Janelle W. Li, M. Ruhul Abid, Frank W. Sellke. DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. Physiological Reports 2024; 12(5) doi: 10.14814/phy2.15976
|
| 36 |
Alfredo Mauriello, Adriana Correra, Riccardo Molinari, Gerardo Elia Del Vecchio, Viviana Tessitore, Antonello D’Andrea, Vincenzo Russo. Mitochondrial Dysfunction in Atrial Fibrillation: The Need for a Strong Pharmacological Approach. Biomedicines 2024; 12(12): 2720 doi: 10.3390/biomedicines12122720
|
| 37 |
Pankaj Kumar Jha, Heta Shukla, Altaf Makwana, Ashutosh Kakkad. Type 2 Diabetes in 2024 - From Early Suspicion to Effective Management. 2023; doi: 10.5772/intechopen.1002309
|
| 38 |
Alfredo Caturano, Erica Vetrano, Raffaele Galiero, Celestino Sardu, Luca Rinaldi, Vincenzo Russo, Marcellino Monda, Raffaele Marfella, Ferdinando Carlo Sasso. Advances in the Insulin–Heart Axis: Current Therapies and Future Directions. International Journal of Molecular Sciences 2024; 25(18): 10173 doi: 10.3390/ijms251810173
|